451 related articles for article (PubMed ID: 11743649)
1. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples.
Dahse R; Utting M; Werner W; Schimmel B; Claussen U; Junker K
Int J Oncol; 2002 Jan; 20(1):107-15. PubMed ID: 11743649
[TBL] [Abstract][Full Text] [Related]
2. Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments.
Schlechte HH; Sachs MD; Lenk SV; Brenner S; Rudolph BD; Loening SA
Cancer Detect Prev; 2000; 24(1):24-32. PubMed ID: 10757120
[TBL] [Abstract][Full Text] [Related]
3. Genomic instability analysis of urine sediment versus tumor tissue in transitional cell carcinoma of the urinary bladder.
Turyn J; Matuszewski M; Schlichtholz B
Oncol Rep; 2006 Jan; 15(1):259-65. PubMed ID: 16328066
[TBL] [Abstract][Full Text] [Related]
4. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses.
Denzinger S; Mohren K; Knuechel R; Wild PJ; Burger M; Wieland WF; Hartmann A; Stoehr R
Hum Pathol; 2006 Feb; 37(2):143-51. PubMed ID: 16426913
[TBL] [Abstract][Full Text] [Related]
5. [The diagnostic value of microsatellite LOH analysis and the prognostic relevance of angiogenic gene expression in urinary bladder cancer].
Szarvas T
Magy Onkol; 2009 Dec; 53(4):385-9. PubMed ID: 20071311
[TBL] [Abstract][Full Text] [Related]
6. Detection of loss of heterozygosity in the p53 tumor-suppressor gene with PCR in the urine of patients with bladder cancer.
Friedrich MG; Erbersdobler A; Schwaibold H; Conrad S; Huland E; Huland H
J Urol; 2000 Mar; 163(3):1039-42. PubMed ID: 10688045
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma.
Paterson RF; Ulbright TM; MacLennan GT; Zhang S; Pan CX; Sweeney CJ; Moore CR; Foster RS; Koch MO; Eble JN; Cheng L
Cancer; 2003 Nov; 98(9):1830-6. PubMed ID: 14584063
[TBL] [Abstract][Full Text] [Related]
8. Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer.
Utting M; Werner W; Dahse R; Schubert J; Junker K
Clin Cancer Res; 2002 Jan; 8(1):35-40. PubMed ID: 11801538
[TBL] [Abstract][Full Text] [Related]
9. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment.
Bartoletti R; Dal Canto M; Cai T; Piazzini M; Travaglini F; Gavazzi A; Rizzo M
Oncol Rep; 2005 Mar; 13(3):531-7. PubMed ID: 15706429
[TBL] [Abstract][Full Text] [Related]
10. Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder.
Edwards J; Duncan P; Going JJ; Grigor KM; Watters AD; Bartlett JM
Br J Cancer; 2001 Dec; 85(12):1894-9. PubMed ID: 11747332
[TBL] [Abstract][Full Text] [Related]
11. P53 mutations as an identification marker for the clonal origin of bladder tumors and its recurrences.
Dahse R; Gärtner D; Werner W; Schubert J; Junker K
Oncol Rep; 2003; 10(6):2033-7. PubMed ID: 14534739
[TBL] [Abstract][Full Text] [Related]
12. Clonal origin of lymph node metastases in bladder carcinoma.
Jones TD; Carr MD; Eble JN; Wang M; Lopez-Beltran A; Cheng L
Cancer; 2005 Nov; 104(9):1901-10. PubMed ID: 16196038
[TBL] [Abstract][Full Text] [Related]
13. [Loss of heterozygosity fine mapping of chromosome 17p13 in transitional cell carcinoma of human urinary bladder].
Zheng S; Zhang J; Di X; Xiao Z; Wang D; Li C; He Z; Han N; Guo S; Cheng S; Gao Y
Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(3):161-3. PubMed ID: 11953150
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite alterations at chromosomes 9p, 13q, and 17p in nonmuscle-invasive transitional cell carcinomas of the urinary bladder.
Erbersdobler A; Friedrich MG; Schwaibold H; Henke RP; Huland H
Oncol Res; 1998; 10(8):415-20. PubMed ID: 10100758
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis.
Curigliano G; Ferretti G; Flamini G; Goldhirsch A; de Braud F; Calabro MG; Mandaly M; Nole F; De Pas T; D'Addessi A; Cittadini A
Anticancer Res; 2001; 21(4B):3015-20. PubMed ID: 11712804
[TBL] [Abstract][Full Text] [Related]
16. Molecular serological diagnosis in transitional cell bladder cancer.
von Knobloch R; Brandt H; Hofmann R
Ann N Y Acad Sci; 2004 Jun; 1022():70-5. PubMed ID: 15251942
[TBL] [Abstract][Full Text] [Related]
17. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
Lininger RA; Zhuang Z; Man Y; Park WS; Emmert-Buck M; Tavassoli FA
Mod Pathol; 1999 Dec; 12(12):1083-9. PubMed ID: 10619258
[TBL] [Abstract][Full Text] [Related]
18. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.
Wallerand H; Bakkar AA; de Medina SG; Pairon JC; Yang YC; Vordos D; Bittard H; Fauconnet S; Kouyoumdjian JC; Jaurand MC; Zhang ZF; Radvanyi F; Thiery JP; Chopin DK
Carcinogenesis; 2005 Jan; 26(1):177-84. PubMed ID: 15347601
[TBL] [Abstract][Full Text] [Related]
19. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of p53 gene mutations in bladder tumors.
Lorenzo-Romero JG; Salinas-Sánchez AS; Giménez-Bachs JM; Sánchez-Sánchez F; Escribano-Martínez J; Segura-Martín M; Hernandez-Millán IR; Virseda-Rodríguez JA
J Urol; 2003 Feb; 169(2):492-9. PubMed ID: 12544295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
